MA40589A - Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines - Google Patents
Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humainesInfo
- Publication number
- MA40589A MA40589A MA040589A MA40589A MA40589A MA 40589 A MA40589 A MA 40589A MA 040589 A MA040589 A MA 040589A MA 40589 A MA40589 A MA 40589A MA 40589 A MA40589 A MA 40589A
- Authority
- MA
- Morocco
- Prior art keywords
- progenitor cells
- frizzled
- jagged
- ventricular progenitor
- ventricular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Cette invention concerne jagged 1 et frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiomyogènes humaines, en particulier des cellules progénitrices qui se différencient préférentiellement en cellules musculaires ventriculaires cardiaques. Par conséquent, l'invention concerne des cellules progénitrices ventriculaires humaines (hvp), et des procédés de séparation in vitro de cellules progénitrices ventriculaires islet 1+/jagged 1+ et/ou de cellules progénitrices ventriculaires islet1+/frizzled 4+ et/ou de cellules progénitrices ventriculaires islet 1+/jagged 1+/frizzled 4+, et leur expansion et propagation à grande échelle. D'importantes populations clonales de cellules progénitrices ventriculaires jagged 1+ et/ou frizzled 4+ isolées sont également décrites. L'invention concerne également des procédés d'utilisation in vivo des cellules progénitrices ventriculaires jagged 1+ et/ou frizzled 4+ pour la réparation cardiaque ou pour l'amélioration de la fonction cardiaque. Des procédés d'utilisation des cellules progénitrices ventriculaires jagged 1+ et/ou frizzled 4+ pour le criblage de toxicité cardiaque de composés d'essai sont également décrits.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462040892P | 2014-08-22 | 2014-08-22 | |
US201562194016P | 2015-07-17 | 2015-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40589A true MA40589A (fr) | 2017-06-28 |
Family
ID=54062813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040589A MA40589A (fr) | 2014-08-22 | 2015-08-21 | Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines |
Country Status (6)
Country | Link |
---|---|
US (1) | US10597637B2 (fr) |
EP (2) | EP3183337B1 (fr) |
JP (2) | JP6738808B2 (fr) |
DK (1) | DK3183337T3 (fr) |
MA (1) | MA40589A (fr) |
WO (1) | WO2016029122A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3183337B1 (fr) | 2014-08-22 | 2019-02-06 | Procella Therapeutics AB | Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines |
US10596200B2 (en) | 2014-08-22 | 2020-03-24 | Procella Therapeutics Ab | Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells |
FI3417073T3 (fi) * | 2016-02-19 | 2023-11-01 | Procella Therapeutics Ab | Geenimarkkereita humaanien sydämen kammion progenitorisolujen siirtämiselle |
WO2017192606A1 (fr) * | 2016-05-02 | 2017-11-09 | Emory University | Procédés de production de cellules de type cardiaque spécialisées à partir de cellules souches |
US10508263B2 (en) * | 2016-11-29 | 2019-12-17 | Procella Therapeutics Ab | Methods for isolating human cardiac ventricular progenitor cells |
US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
CA3072579A1 (fr) * | 2017-08-23 | 2019-02-28 | Procella Therapeutics Ab | Utilisation de neuropiline-1 (nrp1) en tant que marqueur de surface cellulaire pour isoler des cellules progenitrices ventriculaires cardiaques humaines |
CN109189051A (zh) * | 2018-10-29 | 2019-01-11 | 江苏罗思韦尔电气有限公司 | 一种基于T-Box的故障存储及处理方法 |
WO2023278382A1 (fr) | 2021-06-29 | 2023-01-05 | Staffan Holmin | Canule d'administration endoluminale |
CA3231501A1 (fr) * | 2021-09-13 | 2023-03-16 | Steven Kattman | Procedes de production de cellules progenitrices cardiaques engagees |
WO2023199113A1 (fr) | 2022-04-15 | 2023-10-19 | Smartcella Solutions Ab | Compositions et procédés d'administration à médiation par des exosomes d'agents d'arnm |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US5561384A (en) | 1995-11-08 | 1996-10-01 | Advanced Micro Devices, Inc. | Input/output driver circuit for isolating with minimal power consumption a peripheral component from a core section |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
US5945577A (en) | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
US7166280B2 (en) | 2000-04-06 | 2007-01-23 | Franco Wayne P | Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease |
EP1435977A4 (fr) | 2001-09-19 | 2005-06-08 | Ford Henry Health System | Transplantation cardiaque de cellules souches pour le traitement de l'insuffisance cardiaque |
WO2004070013A2 (fr) | 2003-01-31 | 2004-08-19 | The Regents Of The University Of California | Utilisation de l'ilot 1 comme marqueur pour isoler ou produire des cellules souches |
US20080038229A1 (en) | 2006-08-08 | 2008-02-14 | Minguell Jose J | Intracoronary injection of a mixture of autologous bone marrow derived mononuclear cells and autologous bone marrow derived mesenchymal stem cells for utilization and rescue of infarcted myocardium |
US20100166714A1 (en) | 2006-11-02 | 2010-07-01 | The General Hospital Corporation | Cardiovascular stem cells, methods for stem cell isolation, and uses thereof |
EP2087098A4 (fr) | 2006-11-09 | 2010-03-31 | Univ Johns Hopkins | Dedifferenciation de cardiomyocytes mammaliens adultes en cellules souches cardiaques |
US20080182328A1 (en) | 2006-12-19 | 2008-07-31 | The Burnham Institute | Mammalian extraembryonic endoderm cells and methods of isolation |
JP2010517578A (ja) | 2007-02-09 | 2010-05-27 | ザ ジェネラル ホスピタル コーポレイション | Islet1+系統に入るように細胞を誘導する方法およびそれを拡大する方法 |
WO2009017460A1 (fr) | 2007-07-31 | 2009-02-05 | Es Cell International Pte Ltd | Procédé d'identification et de sélection de cardiomyocytes |
CA2743701A1 (fr) * | 2007-11-30 | 2009-06-11 | New York Medical College | Compositions comprenant des inhibiteurs hdac et procedes permettant de les utiliser pour reparer la fonction des cellules souches et empecher l'insuffisance cardiaque |
US20120027807A1 (en) * | 2008-10-09 | 2012-02-02 | The General Hospital Corporation | Tissue engineered myocardium and methods of production and uses thereof |
EP2529008A1 (fr) * | 2010-01-26 | 2012-12-05 | Université Libre de Bruxelles | Outils pour isoler et suivre des cellules progénitrices cardiovasculaires |
US20130209415A1 (en) * | 2010-06-03 | 2013-08-15 | The Board Of Trustees Of The Leland Stanford Junior University | Purified compositions of cardiovascular progenitor cells |
US20120009158A1 (en) * | 2010-06-18 | 2012-01-12 | The General Hospital Corporation | VENTRICULAR INDUCED PLURIPOTENT STEM (ViPS) CELLS FOR GENERATION OF AUTOLOGOUS VENTRICULAR CARDIOMYOCYTES AND USES THEREOF |
WO2012070014A2 (fr) | 2010-11-26 | 2012-05-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Identification de nouveaux marqueurs de surface cellulaire pour des cellules progénitrices pancréatiques et des cellules endodermiques définies |
WO2012162741A1 (fr) * | 2011-06-01 | 2012-12-06 | Monash University | Enrichissement de cardiomyocytes |
WO2013056072A1 (fr) * | 2011-10-13 | 2013-04-18 | Wisconsin Alumni Research Foundation | Génération de cardiomyocytes à partir de cellules souches pluripotentes humaines |
JP5920741B2 (ja) | 2012-03-15 | 2016-05-18 | iHeart Japan株式会社 | 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法 |
US9234176B2 (en) * | 2012-11-13 | 2016-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically defined production of cardiomyocytes from pluripotent stem cells |
EP2968416A4 (fr) | 2013-03-15 | 2016-08-17 | Fate Therapeutics Inc | Essai d'activité biologique de cellules pour un potentiel thérapeutique |
US10888588B2 (en) | 2013-10-18 | 2021-01-12 | Icahn School Of Medicine At Mount Sinai | Directed cardiomyocyte differentiation and ventricular specification of stem cells |
ES2689804T3 (es) | 2013-11-20 | 2018-11-15 | Miltenyi Biotec Gmbh | Composiciones de subpoblaciones de cardiomiocitos |
JP6571115B2 (ja) * | 2014-02-12 | 2019-09-04 | ジェネンテック, インコーポレイテッド | 抗jagged1抗体及び使用方法 |
EP3138906B1 (fr) * | 2014-05-01 | 2019-08-21 | iHeart Japan Corporation | Cellules progénitrices cardiaques positives pour le cd82 |
EP3183337B1 (fr) | 2014-08-22 | 2019-02-06 | Procella Therapeutics AB | Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines |
US10596200B2 (en) | 2014-08-22 | 2020-03-24 | Procella Therapeutics Ab | Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells |
JP2018510649A (ja) | 2015-02-17 | 2018-04-19 | ユニバーシティー ヘルス ネットワーク | 洞房結節様ペースメーカー心筋細胞および心室様心筋細胞を作製および使用するための方法 |
FI3417073T3 (fi) | 2016-02-19 | 2023-11-01 | Procella Therapeutics Ab | Geenimarkkereita humaanien sydämen kammion progenitorisolujen siirtämiselle |
US10508263B2 (en) | 2016-11-29 | 2019-12-17 | Procella Therapeutics Ab | Methods for isolating human cardiac ventricular progenitor cells |
-
2015
- 2015-08-21 EP EP15759585.1A patent/EP3183337B1/fr active Active
- 2015-08-21 US US14/832,324 patent/US10597637B2/en active Active
- 2015-08-21 EP EP18211720.0A patent/EP3524673A1/fr active Pending
- 2015-08-21 DK DK15759585.1T patent/DK3183337T3/en active
- 2015-08-21 MA MA040589A patent/MA40589A/fr unknown
- 2015-08-21 WO PCT/US2015/046309 patent/WO2016029122A1/fr active Application Filing
- 2015-08-21 JP JP2017529972A patent/JP6738808B2/ja active Active
-
2020
- 2020-04-22 JP JP2020076020A patent/JP2020120677A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3183337A1 (fr) | 2017-06-28 |
JP6738808B2 (ja) | 2020-08-12 |
JP2020120677A (ja) | 2020-08-13 |
DK3183337T3 (en) | 2019-04-01 |
US20160053229A1 (en) | 2016-02-25 |
US10597637B2 (en) | 2020-03-24 |
EP3183337B1 (fr) | 2019-02-06 |
JP2017525393A (ja) | 2017-09-07 |
WO2016029122A1 (fr) | 2016-02-25 |
EP3524673A1 (fr) | 2019-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40589A (fr) | Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines | |
EA201290527A1 (ru) | Способы выделения мононуклеарных клеток, которые включают субпопуляцию мезенхимальных клеток-предшественников, и сосудистых клеток, которые включают субпопуляцию эндотелиальных клеток-предшественников, из пуповинной ткани | |
EA201992610A1 (ru) | Экспансия -t-клеток, композиции и способы их применения | |
EP3388512A4 (fr) | Procédé de séparation et de culture de cellules souches mésenchymateuses à partir de tissu de la gelée de wharton de cordon ombilical | |
EA201890013A1 (ru) | Способы получения tcr гамма дельтат-клеток | |
EP4368728A3 (fr) | Quantification simultanée de l'expression génique dans une région définie par l'utilisateur d'un tissu en coupe transversale | |
EA201890435A1 (ru) | Производные никотинамидмононуклеотида и их применение | |
EA202091333A1 (ru) | Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний | |
PH12016502012A1 (en) | Defined composition gene modified t-cell products | |
MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
EP4292600A3 (fr) | Photorécepteurs et progéniteurs de photorécepteurs produits à partir de cellules souches pluripotentes | |
WO2015154012A8 (fr) | Populations de cellules tueuses naturelles (nk) clonogéniques et procédés de production et d'utilisation de telles populations | |
CA3011049A1 (fr) | Compositions pour lier des domaines de liaison a l'adn et des domaines de clivage | |
EA201790357A1 (ru) | Способ получения клеток-предшественников зрелой печени | |
EA202091219A1 (ru) | Культивирование плаценты с целью выделения экзосом | |
PH12014502508B1 (en) | hUTC MODULATION OF PRO-INFLAMMATORY MEDIATORS OF LUNG AND PULMONARY DISEASES AND DISORDERS | |
MX2019007890A (es) | Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte. | |
WO2015181831A3 (fr) | Procédé pour cibler un glioblastome avec des cellules souches mésenchymateuses de la gelée de wharton (cms-gw) dérivées de cordon ombilical humain | |
EA201790025A1 (ru) | Создание банка мезенхимальных стромальных клеток из объединенных мононуклеарных клеток нескольких доноров костного мозга | |
MX2016016756A (es) | Terapia con células madre en patologías endometriales. | |
WO2006102209A3 (fr) | Cellules cd34(+) et leurs procedes d'utilisation | |
MX2021012041A (es) | Metodos para promover la diferenciacion de celulas epiteliales timicas y progenitores de celulas epiteliales timicas de celulas madre pluripotentes, celulas resultantes y usos de estas. | |
MX2021006515A (es) | Composiciones de methylobacterium para mejorar el rendimiento del maíz. | |
WO2018140850A3 (fr) | Lymphocytes t dérivés de sang de cordon ombilical | |
MX2022001694A (es) | Metodos y composiciones para mejorar el rendimiento de soya. |